Explore: Biotech · Drug Discovery · Medtech · Growth · Pre-Seed · Seed
Medicxi V
Medicxi
Investment Thesis
Support companies with clear product visions to transform patient care, focusing on asset-focused biotechs across all stages of development via a capital-efficient investment strategy.
About Medicxi V
Medicxi is a leading European life sciences venture capital firm that employs a pioneering asset-centric investment model, creating and backing biotechnology companies focused on developing transformative therapies for patients. Medicxi V, a €500 million ($581 million) oversubscribed fund closed in November 2025, continues this strategy by supporting drug hunters and entrepreneurs in building asset-focused biotechs while also investing in existing companies at all development stages. The firm drives financial and intellectual resources toward single assets with clear product visions to maximize value creation.
Sectors
Stages
Geographic focus
Notable Investments
Levicept
Verified 29 March 2026 · Sources: company website, Fusion42 review
Frequently asked questions
- What does Medicxi V invest in?
- Medicxi V invests in Biotech, Drug Discovery and Medtech at the growth, pre-seed, seed, series-a, series-b and series-c stages.
- Which geographies does Medicxi V focus on?
- Medicxi V focuses on Europe, and is headquartered in UK.
- What is Medicxi V's typical check size?
- Medicxi V typically writes checks of $1M to $20M.